CRIS

Curis, Inc. Announcement: Curis, Inc. will present clinical and preclinical data on emavusertib, an IRAK4 inhibitor, at the 30th Annual Meeting of the Society for Neuro-Oncology from November 19-23, 2025.

Presentation Details: Key presentations include analyses of genetic mutation profiles and CNS pharmacokinetics in relapsed/refractory primary CNS lymphoma patients, as well as preliminary safety and efficacy results of emavusertib in combination with ibrutinib.

Ongoing Studies: Emavusertib is being evaluated in multiple studies, including its use in combination therapies for relapsed/refractory primary CNS lymphoma, acute myeloid leukemia, and high-risk myelodysplastic syndrome.

Regulatory Designations: Emavusertib has received Orphan Drug Designation from the FDA and the European Commission for the treatment of primary CNS lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

Inducement Stock Options Granted: Curis, Inc. announced the approval of inducement stock options for two new employees, totaling 84,750 shares, with a grant date of October 1, 2025. The options have a 10-year term and vest over four years.

Focus on Emavusertib Development: Curis is developing emavusertib, an IRAK4 inhibitor, currently in clinical trials for various blood cancers, and has received Orphan Drug Designation from the FDA and European Commission for certain conditions.

Company Overview: Curis, Inc. is focusing its resources on a single drug, an IRAK4 and FLT3 inhibitor, targeting non-Hodgkin lymphoma (NHL) and acute myeloid leukemia (AML), with promising proof-of-concept data in primary central nervous system lymphoma (PCNSL).

Therapeutic Approach: The drug is designed to complement BTK inhibitors by blocking the TLR pathway, potentially leading to higher response rates and complete remission in NHL patients.